Buprenorphine maintenance: A new treatment for opioid dependence

Cleveland Clinic Journal of Medicine

Volumn 74, Issue 7, 2007, Pages 514-520

  Collins, Gregory B ^a   McAllister, Mark S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34547735937     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.74.7.514     Document Type: Article

References (41)

1. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Results from the 2004 National Survey on Drug Use and Health: National Findings (NSDUH Series H-28, DHHS Publication No. SMA-05-4062). Rockville, MD; 2005.
2. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Treatment Episode Data Set: 1993-2003. National Admissions to Substance Abuse Treatment Services (DASIS Series S-29, DHHS Publication No. SMA 05-4118). Rockville, MD; 2005.
3. Office of National Drug Control Policy Drug Policy Information Clearinghouse. Heroin Fact Sheet June 2003. http://www.whitehousedrugpolicy.gov/drugfact/heroin/index.html. Accessed March 26, 2007.
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, DSM-IV. 4th ed. Washington, DC: American Psychiatric Association; 1994.
5. Hulse GV, English DR, Milne E, Holman CD. The quantification of mortality resulting from the regular use of illicit opiates. Addiction 1999; 94:221-229.
6. Mark TL. Woody GE, Juday T, Klaeber HD. The economic costs of heroin addiction in the United States. Drug Alcohol Depend 2001; 61:195-206.
7. Sees KL, Delucchi KL, Masson C, et al. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of oploid dependence: a randomized controlled trial. JAMA 2000, 283:1303-1310.
8. Collins ED, Kleber HD, Whittington RA, Heitler NE. Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial. JAMA 2005, 294:903-913.
9. Strain EC, Bigelow GE, Liebson IA, Stitzer ML Moderate- vs highdose methadone in the treatment of opioid dependence: a randomized trial. JAMA 1999, 281:1000-1005.
10. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. Effective medical treatment of opiate addiction. JAMA 1998; 280:1936-1943.
11. Marsch LA The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a metaanalysis. Addiction 1998; 93:515-532.
12. O'Connor PG. Methods of detoxification and their role in treating patients with opioid dependence. JAMA 2005; 294:961-963.
13. Bartu A. Freeman NC. Gawthorne GS, Allsop SJ, Quigley AJ Characteristics, retention and readmissions of opioid-dependent clients treated with oral naltrexone. Drug Alcohol Rev 2002; 21:335-340.
14. McLellan AT, Arndt IO, Metzger DS, Woody GE, O'Brien CP. The effects of psychosocial services in substance abuse treatment. JAMA 1993; 269:1953-1959.
15. Dole VP, Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction. A clinical trial with methadone hydrochloride. JAMA 1965; 193:646-650.
16. Jaffe JH, O'Keeffe C. From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States. Drug Alcohol Depend 2003; 70(suppl)53-Sl1.
17. Rettig RA, Yarmolinsky A, eds. Federal Regulation of Methadone Treatment. Washington, DC: Institute of Medicine, National Academy Press, 1995.
18. Fiellin DA. O'Connor PG. New federal initiatives to enhance the medical treatment of opioid dependence. Ann Intern Med 2002, 137:688-692.
19. Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry 1978; 35:501-516.
20. Walsh SL, Preston KL, Bigelow GE, Stitzer ML Acute administration of buprenorphine in humans: partial agonist and blockade effects. J Pharmacol Exp Ther 1995, 274:361-372.
21. Johnson RE, Strain EC, Amass L Buprenorphine: how to use it right. Drug Alcohol Depend 2003, 70(suppl):559-S77.
22. Comer SD, Sullivan MA. Walker EA. Comparison of intravenous buprenorphine and methadone self-administration by recently detoxified heroin-dependent individuals. J Pharmacol Exp Ther 2005, 315:1320-1330.
23. Stoller KB, Bigelow GE, Walsh SL, Strain EC. Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology (Berl) 2001; 154:230-242.
24. Walsh SI, June HL. Schuh KJ, Preston KL, Bigelow GE, Stitzer ML Effects of buprenorphine and methadone in methadone-maintained subjects. Psychopharmacology (Berl) 1995; 119:268-276.
25. Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction (TIP Series 40, DHHS Publication No. SMA 04-3939). Rockville, MD; 2004.
26. Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs 2003; 35:253-259.
27. Amass L. Bickel WK, Crean JP, Blake J, Higgins ST. Alternate-day buprenorphine dosing is preferred to daily dosing by opioid-dependent: humans. Psychopharmacology (Berl) 1998; 136:217-225.
28. Ling W, Amass L. Shoptaw S. et al; Buprenorphlne Study Protocol Group. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for oploid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction 2005; 100:1090-1100.
29. Auriacombe M. Fatseas M, Dubernet J, Daulouede JP, Tignol J. French field experience with buprenorphine. Am J Addict 2004, 13(suppl 1):S17-S28.
30. Cicero TJ, Inciardi JA. Potential for abuse of buprenorphine in officebased treatment of opioid dependence. N Engl J Med 2005; 353:1863-1865.
31. Reynaud M, Tracqui A, Petit G, Potard D, Courty P. Six deaths linked to misuse of buprenorphin-benzodiazepine combinations. Am J Psychiatry 1998,155:448-449.
32. West SL, O'Neal KK, Graham CW. A meta-analysis comparing the effectiveness of buprenorphine and methadone. J Subst Abuse 2000, 12:405-414.
33. Ling W, Wesson DR. Clinical efficacy of buprenorphine: comparisons to methadone and placebo. Drug Alcohol Depend 2003; 70(suppl)-S49-S57.
34. Fiellin DA, Pantalon MV, Pakes A O'Connor PG, Chawarski M, Schottenfeld RS. Treatment of heroin dependence with buprenorphine in primary care. Am J Drug Alcohol Abuse 2002; 28:231-241.
35. O'Connor PG, Oliveto AH, Shi JM, et al. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. Am J Med 1998; 105:100-105.
36. O'Connor PG, Carroll KM, Shi JM, Schottenfeld RS, Kosten TR, Rounsaville BJ. Three methods of opioid detoxification in a primary care setting. A randomized trial. Ann Intern Med 1997, 127:526-530.
37. Amass L. Ling W, Freese TE, et al. Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience. Am J Addict 2004; 13(suppl 1): S42-S66.
38. Fiellin DA. O'Connor PG, Chawarski M. Schottenfeld RS. Processes of care during a randomized trial of office-based treatment of opioid dependence in primary care. Am J Addict 2004,13(suppl 1):S67-S78.
39. Sullivan LE, Chawarski M, O'Connor PG, Schottenfeld RS, Fiellin DA. The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment? Drug Alcohol Depend 2005, 79:113-116.
40. West JC, Kosten TR, Wilk J. et al. Challenges in increasing access to buprenorphine treatment for opiate addiction. Am J Addict 2004, 13(suppl 1):s8-s16.
41. Substance Abuse and Mental Health Services Administration. Buprenorphine Physician Locator. Available at: http://buprenorphine.samhsa.gov/. Accessed 8/24/2006.